Agenus Inc.(AGEN)

Biotechnology · Lexington, MA

$8.23-0.50 (-5.73%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Lexington, MA

81 employees

www.agenusbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Garo H. Armen

View full financials

AGEN Free Cash Flow Yield Metrics

FREE CASH FLOW YIELD

N/A

FREE CASH FLOW YIELD AVG TTM

N/A

FREE CASH FLOW YIELD AVG 3Y

N/A

FREE CASH FLOW YIELD AVG 5Y

N/A

FREE CASH FLOW YIELD AVG 10Y

N/A

FREE CASH FLOW YIELD AVG 15Y

N/A

FREE CASH FLOW YIELD AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NAME

MARKET CAP

FREE CASH FLOW YIELD

TTM

Agenus Inc. (AGEN)

$342.72M

N/A

Artiva Biotherapeutics, Inc. (ARTV)vs ›

$340.28M

N/A

ClearPoint Neuro, Inc. (CLPT)vs ›

$337.38M

N/A

Embecta Corp. (EMBC)vs ›

$353.30M

46.59%

52.29%

21.98%

21.35%

Enanta Pharmaceuticals, Inc. (ENTA)vs ›

$352.72M

N/A

3.10%

3.51%

4.59%

Fennec Pharmaceuticals Inc. (FENC)vs ›

$357.79M

N/A

15.24%

Opus Genetics, Inc. (IRD)vs ›

$354.62M

N/A

Cabaletta Bio, Inc. (CABA)vs ›

$326.11M

N/A

C4 Therapeutics, Inc. (CCCC)vs ›

$325.07M

N/A

CapsoVision, Inc. (CV)vs ›

$322.44M

N/A

DATE

FREE CASH FLOW YIELD

2013-05-10

0.04%

2013-05-09

0.04%

2013-05-08

0.04%

2013-05-07

0.05%

2013-05-06

0.04%

2013-05-03

0.04%

2013-05-02

0.04%

2013-05-01

0.04%

2013-04-30

0.04%

2013-04-29

0.04%

2013-04-26

0.04%

2013-04-25

0.04%

2013-04-24

0.04%

2013-04-23

0.04%

2013-04-22

0.04%

2013-04-19

0.04%

2013-04-18

0.05%

2013-04-17

0.04%

2013-04-16

0.04%

2013-04-15

0.04%

2013-04-12

0.04%

2013-04-11

0.04%

2013-04-10

0.04%

2013-04-09

0.04%

2013-04-08

0.04%

2013-04-05

0.05%

2013-04-04

0.05%

2013-04-03

0.05%

2013-04-02

0.05%

2013-04-01

0.05%

2013-03-28

0.05%

2013-03-27

0.05%

2013-03-26

0.05%

2013-03-25

0.05%

2013-03-22

0.05%

2013-03-21

0.05%

2013-03-20

0.04%

2013-03-19

0.04%

2013-03-18

0.00%

2013-03-15

0.00%

2013-03-14

0.00%

2013-03-13

0.00%

2013-03-12

0.00%

2013-03-11

0.00%

2013-03-08

0.00%

2013-03-07

0.00%

2013-03-06

0.00%

2013-03-05

0.00%

2013-03-04

0.00%

2013-03-01

0.00%

2013-02-28

0.00%

2013-02-27

0.00%

2013-02-26

0.00%

2013-02-25

0.00%

2013-02-22

0.00%

2013-02-21

0.00%

2013-02-20

0.00%

2013-02-19

0.00%

2013-02-15

0.00%

2013-02-14

0.00%

2013-02-13

0.00%

2013-02-12

0.00%

2013-02-11

0.00%

2013-02-08

0.00%

2013-02-07

0.00%

2013-02-06

0.00%

2013-02-05

0.00%

2013-02-04

0.00%

2013-02-01

0.00%

2013-01-31

0.00%

2013-01-30

0.00%

2013-01-29

0.00%

2013-01-28

0.00%

2013-01-25

0.00%

2013-01-24

0.00%

2013-01-23

0.00%

2013-01-22

0.00%

2013-01-18

0.00%

2013-01-17

0.00%

2013-01-16

0.00%

2013-01-15

0.00%

2013-01-14

0.00%

2013-01-11

0.00%

2013-01-10

0.00%

2013-01-09

0.00%

2013-01-08

0.00%

2013-01-07

0.00%

2013-01-04

0.00%

2013-01-03

0.00%

2013-01-02

0.00%

2012-12-31

0.00%

2012-12-28

0.00%

2012-12-27

0.00%

2012-12-26

0.00%

2012-12-24

0.00%

2012-12-21

0.00%

2012-12-20

0.00%

2012-12-19

0.00%

2012-12-18

0.00%

2012-12-17

0.00%

2012-12-14

0.00%

2012-12-13

0.00%

2012-12-12

0.00%

2012-12-11

0.00%

2012-12-10

0.00%

2012-12-07

0.00%

2012-12-06

0.00%

2012-12-05

0.00%

2012-12-04

0.00%

2012-12-03

0.00%

2012-11-30

0.00%

2012-11-29

0.00%

2012-11-28

0.00%

2012-11-27

0.00%

2012-11-26

0.00%

2012-11-23

0.00%

2012-11-21

0.00%

2012-11-20

0.00%

2012-11-19

0.00%

2012-11-16

0.00%

2012-11-15

0.00%

2012-11-14

0.00%

2012-11-13

0.00%

2012-11-12

0.00%

2012-11-09

0.00%

2012-11-08

0.00%

2012-11-07

0.01%

2012-11-06

0.01%

2012-11-05

0.01%

2012-11-02

0.01%

2012-11-01

0.01%

2012-10-31

0.01%

2012-10-26

0.01%

2012-10-25

0.01%

2012-10-24

0.01%

2012-10-23

0.01%

2012-10-22

0.01%

2012-10-19

0.01%

2012-10-18

0.01%

2012-10-17

0.01%

2012-10-16

0.01%

2012-10-15

0.01%

2012-10-12

0.01%

2012-10-11

0.01%

2012-10-10

0.01%

2012-10-09

0.01%

2012-10-08

0.01%

2012-10-05

0.01%

2012-10-04

0.01%

2012-10-03

0.01%

2012-10-02

0.01%

2012-10-01

0.01%

2012-09-28

0.01%

2012-09-27

0.01%

2012-09-26

0.01%

2012-09-25

0.01%

2012-09-24

0.01%

2012-09-21

0.01%

2012-09-20

0.01%

2012-09-19

0.01%

2012-09-18

0.01%

2012-09-17

0.01%

2012-09-14

0.01%

2012-09-13

0.01%

2012-09-12

0.01%

2012-09-11

0.01%

2012-09-10

0.01%

2012-09-07

0.01%

2012-09-06

0.01%

2012-09-05

0.01%

2012-09-04

0.01%

2012-08-31

0.01%

2012-08-30

0.01%

2012-08-29

0.01%

2012-08-28

0.01%

2012-08-27

0.01%

2012-08-24

0.01%

2012-08-23

0.01%

2012-08-22

0.01%

2012-08-21

0.01%

2012-08-20

0.01%

2012-08-17

0.01%

2012-08-16

0.01%

2012-08-15

0.01%

2012-08-14

0.01%

2012-08-13

0.01%

2012-08-10

0.01%

2012-08-09

0.01%

Free Cash Flow Yield: N/A

AGEN Free Cash Flow Yield Chart

AGEN Free Cash Flow Yield Metrics

AGEN Competitors' Free Cash Flow Yield

Yield Comparison

Free Cash Flow Yield Formula & Definition

AGEN Free Cash Flow Yield History

Related Metrics